Paper Details

  1. Home
  2. Paper Details

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Author: BahloJasmin, BöttcherSebastian, CramerPaula, DöhnerHartmut, EichhorstBarbara, EngelkeAnja, FinkAnna Maria, FischerKirsten, GhiaPaolo, GoedeValentin, HallekMichael, HerlingCarmen Diana, HerlingMarco, KnebaMichael, KovacsGabor, KreuzerKarl-Anton, LangerbeinsPetra, MarltonPaula, MaurerChristian, SeymourJohn F, StilgenbauerStephan, TauschEugen, WendtnerClemens-Martin, von TresckowJulia

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for chronic lymphocytic leukemia (CLL). This long-term follow-up study examines the safety and efficacy of FC and FCR in treatment-naïve patients with CLL.
Paper Details　
Original Abstract of the Article :
Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial report...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2015-06-651125

データ提供：米国国立医学図書館（NLM）

Fighting Chronic Lymphocytic Leukemia: A Tale of Two Therapies

The fight against chronic lymphocytic leukemia (CLL), a cancer that affects white blood cells, is an ongoing battle. This research delves into the effectiveness of two chemoimmunotherapy regimens, FC and FCR, in battling this relentless disease. Think of these therapies as two different desert oases, each with its own unique advantages and challenges.

The research team compared the long-term efficacy and safety of FC and FCR treatments in patients with CLL. Their findings revealed that FCR treatment, which incorporates the antibody rituximab, was associated with a longer progression-free survival than FC treatment. This is akin to one oasis offering a more sustainable source of water, helping travelers endure the challenges of the desert.

A Deeper Understanding of CLL: Tailoring Treatment to Genetic Subtypes

This research also highlights the significance of tailoring treatments to specific genetic subtypes of CLL. The authors found that FCR therapy was particularly effective in patients with a specific genetic mutation, IGHV MUT. This is like discovering that certain oases offer different types of water, suited to the specific needs of different species of desert animals.

Navigating the Desert of Leukemia Treatment: Making Informed Choices

The study also sheds light on the potential side effects of these therapies. FCR therapy was associated with a higher rate of prolonged neutropenia, a condition that weakens the immune system. This reminds us that even the most effective therapies can come with their own set of challenges. It is crucial to weigh the benefits and risks, just like a camel navigating a desert needs to choose its path wisely.

Dr. Camel's Conclusion

This research underscores the importance of personalized medicine, tailoring treatments to the specific needs of each individual patient. The findings provide crucial insights into the effectiveness of FCR therapy and its potential benefits for patients with CLL. However, it also emphasizes the importance of carefully monitoring patients for potential side effects and making informed decisions in consultation with a healthcare professional.

Date :
  1. Date Completed 2016-06-05
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26486789

DOI: Digital Object Identifier

10.1182/blood-2015-06-651125

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.